Herbert Ho-Fung Loong
Cedars-Sinai Medical Center · 351 works · 9,140 citations · h-index 42
Top works
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial
- Overview of current systemic management of EGFR-mutant NSCLC
- NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
- First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
- Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
- Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma
- COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
- 1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088
- Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
- 1349P Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases
- A phase II study of concurrent cetuximab–cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma
- A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
- Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts
- Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation
- Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
- Primary cardiac sarcomas: A multi‐national retrospective review
- Update on the Management and Therapeutic Monitoring of Advanced Nasopharyngeal Cancer